Virus Diseases
Conditions
Brief summary
Continued symptoms of acute COVID-19 and new symptoms according to long-COVID illness.
Detailed description
A cause, non-elective hospitalisation and/or death, within 28 days of randomisation., Participant reported symptoms daily for 7 days, weekly for 28 days and at 3 and 6 months., Contacts with health services reported by paticipants and/or captured by review for health registries., New infections in the household reported by the participants., Evaluation of overall safety of drugs by the monitoring of adverse events (AEs as defined in the ISAs)., Well-being, symptoms and health care utilisation., Resource use and cost data.
Interventions
DRUGRITONAVIR
DRUGNIRMATRELVIR
DRUGPlacebo: Round
DRUGwhite tablet with breakmarks on one side
DRUGno imprints 8 x 8 mm; Maydis amylum 10%
DRUGCellulosum microcrist. 89%
DRUGMagnesii stearas 0
DRUG5% and Silica colloid. anhydr. 0
DRUG5%
Sponsors
Helse Bergen HF
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Continued symptoms of acute COVID-19 and new symptoms according to long-COVID illness. | — |
Secondary
| Measure | Time frame |
|---|---|
| A cause, non-elective hospitalisation and/or death, within 28 days of randomisation., Participant reported symptoms daily for 7 days, weekly for 28 days and at 3 and 6 months., Contacts with health services reported by paticipants and/or captured by review for health registries., New infections in the household reported by the participants., Evaluation of overall safety of drugs by the monitoring of adverse events (AEs as defined in the ISAs)., Well-being, symptoms and health care utilisation., Resource use and cost data. | — |
Countries
Norway
Outcome results
None listed